Want to see AKTX full AI Analyst Report?
AKTX Stock Chart & Stats
$7.87
-$0.24(-2.76%)
At close: 4:00 PM EDT
$7.87
-$0.24(-2.76%)
Day’s Range― - ―
52-Week Range$3.02 - $49.60
Previous Close$8.46
Volume52.72K
Average Volume (3M)59.66K
Market Cap
$18.97M
Enterprise Value$11.29
Total Cash (Recent Filing)$7.69M
Total Debt (Recent Filing)$693.00K
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Apr 21, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1600.00
Shares Outstanding1,946,982
10 Day Avg. Volume87,905
30 Day Avg. Volume59,663
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.50Price Target Upside262.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-8.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces interest and refinancing pressure, giving Akari greater flexibility to direct available capital toward clinical development. This is a durable balance-sheet strength, although it does not offset the company’s need for future funding.
Focused Therapeutic StrategyA defined focus on autoimmune and inflammatory diseases can concentrate scarce research resources and support specialized scientific expertise. Concentration in complement and immune pathways may also create a coherent platform for advancing related investigational programs.
Access To FinancingApproved financing authorities and a recently structured private placement improve the company’s ability to fund operations and clinical work over the medium term. Access to capital is important for a pre-revenue biotech whose value depends on continued development.
Bears Say
No Revenue GenerationAkari has no commercial revenue base to fund research, operating costs or future obligations. Until an investigational product reaches approval and commercialization, the business remains dependent on external capital and clinical progress rather than internally generated income.
Widening LossesThe sharp deterioration in net income indicates rising cost pressure and weaker earnings power while the company remains in development. Persistently widening losses can accelerate depletion of shareholders’ equity and increase the amount of capital required before revenue begins.
Persistent Cash Burn And Dilution RiskNegative operating and free cash flow show that Akari cannot currently finance its activities internally. The shrinking equity base and approved share and warrant issuance capacity increase the likelihood of repeated fundraising, creating ongoing dilution risk for existing holders.
Akari Therapeutics News
AKTX FAQ
What was Akari Therapeutics’s price range in the past 12 months?
Akari Therapeutics lowest stock price was $3.02 and its highest was $49.60 in the past 12 months.
What is Akari Therapeutics’s market cap?
Akari Therapeutics’s market cap is $18.97M.
When is Akari Therapeutics’s upcoming earnings report date?
Akari Therapeutics’s upcoming earnings report date is Apr 21, 2027 which is in 228 days.
How were Akari Therapeutics’s earnings last quarter?
Akari Therapeutics released its earnings results on Aug 13, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$1.04 by $1.04.
Is Akari Therapeutics overvalued?
According to Wall Street analysts Akari Therapeutics’s price is currently Undervalued.
Does Akari Therapeutics pay dividends?
Akari Therapeutics does not currently pay dividends.
What is Akari Therapeutics’s EPS estimate?
Akari Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akari Therapeutics have?
Akari Therapeutics has 1,946,982 shares outstanding.
What happened to Akari Therapeutics’s price movement after its last earnings report?
Akari Therapeutics reported an EPS of $0 in its last earnings report, beating expectations of -$1.04. Following the earnings report the stock price went up 7.714%.
Which hedge fund is a major shareholder of Akari Therapeutics?
Currently, no hedge funds are holding shares in AKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akari Therapeutics
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
AKTX Stock 12 Month Forecast
Average Price Target
$28.50
▲(262.13% Upside)
Technical Analysis
Ownership Overview
25.66% Insiders
7.32% Other Institutional Investors
67.02% Public Companies and
Individual Investors